ReAlta’s CEO Ulrich Thienel and CFO John Rickman are attending the 34th Annual Oppenheimer & Co. Inc. Healthcare Life Sciences Conference February 13-14th, where they are meeting with investors to discuss our latest program developments, including updates on our three Phase 2 clinical trials for hypoxic-ischemic encephalopathy (HIE), acute graft-versus-host disease (GvHD) and acute exacerbations of COPD. Dr. Thienel will be presenting an overview of the company’s platform technology at 2:00pm EST on Tuesday, February 13, 2024.
Dr. Neel Krishna and Dr. Katherine LaVallee, DVM did an outstanding job leading tours of our lab and offices last...
Read MoreWe want to thank Rep. Elaine Luria and Norfolk Mayor Dr. Kenneth Alexander for helping us celebrate the official opening...
Read MoreReAlta Life Sciences is officially part of Team Hope! We are extending our gratitude to the Hope for HIE team...
Read More